KAI-1 expression in pediatric high-grade osteosarcoma

Pediatric and Developmental Pathology

Volumn 9, Issue 3, 2006, Pages 219-224

  Leavey, Patrick J ^a   Timmons, Charles ^a   Frawley, William ^b   Lombardi, Donald ^a   Ashfaq, Raheela ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CD82; KAI 1; Metastasis; osteosarcoma; Pediatrics

Indexed keywords

MEMBRANE PROTEIN; PARAFFIN; PROTEIN KAI 1; TETRASPANIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMATION CENTER; MALE; METASTASIS; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TUMOR BIOPSY; TUMOR NECROSIS;

ADJUVANTS, IMMUNOLOGIC; BIOPSY; BONE NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KANGAI-1 PROTEIN; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33746489290     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/11-05-0137.1     Document Type: Article

References (21)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
2. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep 2002;9:171-175.
3. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998; 10:69-76.
4. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999;59:5724-5731.
5. Wunder JS, Eppert K, Burrow SR, Gogkoz N, Bell RS, Andrulis IL. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 1999;18:783-788.
6. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000;10:1009-1012.
7. Ferrer M, Yunta M, Lazo PA. Pattern of expression of tetraspanin antigen genes in Burkitt lymphoma cell lines. Clin Exp Immunol 1998;113:346-352.
8. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J 1997;11:428-442.
9. Geradts J, Maynard R, Birrer MJ, et al. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohisto-chemical study of archival tissues. Am J Pathol 1999;154:1665-1671.
10. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996;56:1751-1755.
11. Hollander M, Wolfe DE. Nonparametric Statistical Methods. New York: Wiley, 1999.
12. Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003;97:3068-3075.
13. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000;7:339-346.
14. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
15. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002; 94:1397-1404.
16. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000;6: 572-577.
17. Sangiorgi L, Gobbi GA, Lucarelli E, et al. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer 2001;95:156-161.
18. Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol 2001;23:286-289.
19. Serra M, Scotlandi K, Reverter-Branch, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003;21: 536-542.
20. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 2003; 25:282-285.
21. Arihiro K, Inai K. Loss of KAII/CD82 expression in bone and soft tissue tumors is not associated with lung metastasis. Pathol Res Pract 2001;197:627-633.